BAM
MRNA icon

Baldrige Asset Management’s Moderna MRNA Stock Holding History

Baldrige Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$0 Buy
+2
New +$330 ﹤0.01% 442

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Baldrige Asset Management's MRNA Position: Q1 2023 in Review

Baldrige Asset Management opened a new position in Moderna (MRNA) in Q1 2023: 2 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #442 among its holdings.

1,015 funds tracked by Wall St. Rank hold MRNA as of Q1 2023.

  • Baldrige Asset Management held 2 shares of Moderna worth $0 as of Q1 2023.
  • Moderna was a new Baldrige Asset Management position in Q1 2023.
  • Moderna made up ﹤0.01% of Baldrige Asset Management's portfolio in Q1 2023, its #442 holding.
  • 1,015 funds tracked by Wall St. Rank held Moderna as of Q1 2023.

Based on Baldrige Asset Management's 13F filing for Q1 2023, filed 17 Apr 2023.